Literature DB >> 722727

Stereoselective effects of cis- and trans-cyclopropylbis (dioxopiperazines) related to ICRF-159 on metastases of hamster lung adenocarcinoma.

D T Witiak, H J Lee, H D Goldman, B S Zwilling.   

Abstract

The synthesis for cis-4,4' (1,2-cyclopropanediyl)bis(2,6-piperazinedione) (cis-3) is discussed. Stereoselective effects on metastases of cis-3 and the previously reported trans-2 isomer were compared to conformationally mobile ICRF-159 using a Syrian hamster lung adenocarcinoma (LG1002). Whereas ICRF-159 and cis-3 significantly inhibited lung metastases the trans-2 isomer significantly increased the number of metastatic nodules in the lung. Thus, these studies have revealed that, at least in one tumor model, antimetastatic activity can be separated from metastatic potentiating activity by controlling drug geometry.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 722727     DOI: 10.1021/jm00210a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.

Authors:  T Narita; S Yaguchi; T Komatsu; M Takase; A Hoshino; M Inaba; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).

Authors:  E H Herman; V J Ferrans; H B Bhat; D T Witiak
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).

Authors:  T Narita; Y Koide; S Yaguchi; S Kimura; Y Izumisawa; M Takase; M Inaba; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.

Authors:  B S Zwilling; L B Campolito; N A Reiches; T George; D T Witiak
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.